Treatment of advanced prostate cancer

MY Teo, DE Rathkopf, P Kantoff - Annual review of medicine, 2019 - annualreviews.org
The therapeutic landscape of prostate cancer has been transformed over the last decade by
new therapeutics, advanced functional imaging, next-generation sequencing, and better use …

Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations

JJ Tosoian, MA Gorin, AE Ross, KJ Pienta… - Nature Reviews …, 2017 - nature.com
The oligometastatic state has been proposed as an intermediate stage of cancer spread
between localized disease and widespread metastases. With improvements in diagnostic …

Postoperative mortality among surgical patients with COVID-19: a systematic review and meta-analysis

SM Abate, B Mantefardo, B Basu - Patient safety in surgery, 2020 - Springer
Background The coronavirus disease 2019 (COVID-19) pandemic puts perioperative
providers and staff at risk of viral exposure to severe acute respiratory syndrome coronavirus …

[HTML][HTML] Outcomes of cytoreductive radical prostatectomy for oligometastatic prostate cancer on prostate-specific membrane antigen positron emission tomography …

P Rajwa, D Robesti, M Chaloupka, F Zattoni… - European Urology …, 2024 - Elsevier
Background De novo oligometastatic prostate cancer (omPCa) on prostate-specific
membrane antigen (PSMA) positron emission tomography (PET) is a new disease entity and …

Local therapy improves survival in metastatic prostate cancer

SR Leyh-Bannurah, S Gazdovich, L Budäus, E Zaffuto… - European urology, 2017 - Elsevier
Background Treatment of the primary, termed local therapy (LT), may improve survival in
metastatic prostate cancer (mPCa) versus no local therapy (NLT). Objective To assess …

Feasibility and safety of radical prostatectomy for oligo‐metastatic prostate cancer: the Testing Radical prostatectomy in men with prostate cancer and oligo …

P Sooriakumaran, C Wilson, I Rombach… - BJU …, 2022 - Wiley Online Library
Objectives To test the feasibility of randomisation to radical prostatectomy (RP) plus pelvic
lymphadenectomy in addition to standard‐of‐care (SOC) systemic therapy in men with …

Oligometastatic prostate cancer: reality or figment of imagination?

CC Foster, RR Weichselbaum, SP Pitroda - Cancer, 2019 - Wiley Online Library
The term “oligometastatic prostate cancer” refers to a heterogeneous group of disease states
currently defined solely on the basis of clinical features. Oligorecurrent disease, de novo …

Radical prostatectomy in men with oligometastatic prostate cancer: results of a single-institution series with long-term follow-up

G Gandaglia, N Fossati, A Stabile, M Bandini, P Rigatti… - European urology, 2017 - Elsevier
In the absence of data from randomized trials, the role of local treatment in metastatic
prostate cancer (PCa) is gaining interest. Our study aimed to assess perioperative and long …

Does cytoreductive prostatectomy really have an impact on prognosis in prostate cancer patients with low-volume bone metastasis? Results from a prospective case …

T Steuber, KD Berg, MA Røder, K Brasso… - European urology …, 2017 - Elsevier
The impact of cytoreductive radical prostatectomy (CRP) on oncological outcomes in
patients with prostate cancer (PCa) and distant metastases has been demonstrated by …

Novel insights into the management of oligometastatic prostate cancer: a comprehensive review

A Battaglia, G De Meerleer, L Tosco, L Moris… - European urology …, 2019 - Elsevier
Context The current standard of care for metastatic prostate cancer (PCa) is androgen
deprivation therapy (ADT) plus either docetaxel or abiraterone. Growing evidence suggests …